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Granulocytic sarcoma is a rare type of tumor composed of extramedullary
immature cells. The breast location is very rare; it accounts for less than
8% of cases. The present study reports the case of a 36-year-old female
with a medical history of myelodysplastic syndrome. She was referred
because of a lump in the left breast. We have diagnosed a case of
granulocytic sarcoma of the breast by core biopsy. Histology and
immunohistochemistry showed hypercellular smears with immature
myeloid cells. The blast cells were myeloperoxidase positive.
The patient underwent a lumpectomy. Five months later, she developed a
contralateral recurrence, treated by lumpectomy and radiotherapy. Three
years later, she developed a recurrence in the left knee.
We report this case for its rarity and as a note of caution to a physician to
consider myeloid sarcoma in the differential diagnosis of a breast lump, to
provide the correct diagnosis and avoid incorrect treatment of a curable
disease.

Introduction
Granulocytic sarcoma of the breast (GS), also known
as myeloid or chloroma sarcoma, is a rare extramedullary
manifestation of acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS). It accounts for less
than 8% of cases. It was first described by Burns in 1811.
It is characterized by an unusual type of tumor composed
of immature cells outside the bone marrow. The tumor
can arise de-novo or in association with hematological
malignancies [1-5]. Here we present an isolated
recurrence of GS in the breast, with treatment outcomes.

Case presentation
A 36-year-old woman presented with the clinical
history of MDS occurring four years earlier. She had
undergone allogeneic bone marrow transplantation. The
patient was free of disease, but she was subsequently
undergoing therapy for graft-versus-host disease reaction.
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She was referred to our institute with complaints of a
painful mass in the left breast that had been apparent for
one month. On physical exam, we found a well-defined
mass located in the upper outer quadrant of the left breast,
measuring 40 mm, without skin modification.
The complete blood count and peripheral blood
examination were normal. Mammography showed an
asymmetric opacity in the periareolar area without
microcalcifications. Breast ultrasound showed a
heterogenous well-circumscribed mass in the left breast
measuring 40 mm without posterior acoustic shadowing
and internal vascularity (Figure 1).
A core biopsy of the mass was performed. Histology
and immunohistochemistry revealed hypercellular smears
with immature myeloid cells few neutrophils and many
large round cells with the high nuclear-cytoplasmic ratio,
prominent nucleoli, and a moderate amount of granular
cytoplasm (Figure 2). The blast cells were positive for
myeloperoxidase enzyme (MPO), vimentin, and CD117
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and negative for Pan B, and Pan T (Figure 3). The
diagnostic was a breast relapse for her MDS, known as
GS of the breast.

The patient received adjuvant radiotherapy for the left
breast, and contact radiotherapy for the right breast. The
total dose was 36 Gy for both breasts. Three years later
she presented an isolated recurrence in her left knee. The
clinical exam showed a hard mass, measuring 40 mm.
The MRI showed a suspected mass measuring 88×32 mm
with cribriform appearance, infiltrating the ligament and
the tendon of the left knee (Figure 4). The core biopsy and
histologic findings confirmed the recurrence of her
anterior GS. The multidisciplinary committee outlined
surgery, but the patient refused the operation.
Chemotherapy has been challenged due to localized
disease. The patient was then lost again to follow up,
though in good general condition when released.

Figure 1. (A) hyperdense opacity in the periareolar area
without microcalcifications on mammography (yellow
asterisk); (B) a heterogenous well-circumscribed mass,
measured 40 mm in the left breast without posterior
acoustic on ultrasound.
The patient underwent a left breast lumpectomy. In
the macroscopic examination, we found a grayish mass
measuring 50 mm, and the margins were free of disease.
Radiotherapy was proposed for the patient, but she failed
to follow up. Five months later, she consulted for
contralateral breast mass. Upon examination we found a
well-defined mass, measuring 15 mm in the right
submammary fold. She underwent a local excision. The
histologic findings showed a GS of the right breast, with
free margins.

Figure

3. Immunohistochemistry features, (A)
Myeloperoxidase; (B) vimentin; (C) and (D) CD117.
Magnification: 20×.
A

B

Figure 4. MRI sequence T1-weighted with Gadolinium
showed a suspected mass measuring 88×32 mm with
cribriform appearance, infiltrating the ligament and the
tendon of the left knee.

Discussions
Figure 2. Progressive magnification in Hematoxylineosin staining: (A) ×5; (B) × 10; (C) ×20; (D) ×40;
showing hypercellular smears with immature myeloid
cells few neutrophils, megakaryocytes and many large
round cells with the high nuclear-cytoplasmic ratio.

GS of the breast most commonly occurs in patients
with previously diagnosed AML or MDS. The breast is an
uncommon site for presentation of this tumor. It is
characterized by the formation of tumors containing
immature myeloid cells [1, 2, 5-7]. GS can arise in any
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part of the human body, but bones, lymph nodes, soft
tissues, and skin are among the most common sites of
presentation other than the urogenital tract [1, 4, 6].
The rarity of breast GS makes the diagnosis difficult,
often being misdiagnosed as lymphoma, sarcoma, or
breast carcinoma, especially in the absence of bone
marrow invasion. In this case, the patient had a medical
history of the hematological disease, even though with
complete remission [4, 7, 8].
The clinical manifestations of the GS of the breast
are not specific. It often manifests as a palpable mass
that can be either painless or painful. Other symptoms
can be found such as skin involvement and axillary
lymph node, although nipple retraction or discharge or
inversion is not common [1, 4, 7].
Due to their rarity of the condition, radiological
findings are variable. It is difficult to differentiate GS
from benign lesions or other malignant lesions. The
ultrasonography showed a regular or micolobulated
mass with well-defined margins, irregularly shaped,
heterogeneous or hypoechoic with visible posterior
acoustic shadows. Sometimes, it appears with spiculated
or microlobulated margins [5, 7].
On the mammography, the lesions can have regular
or irregular limits usually without microcalcifications (2,
8). Sometimes MRI is used to eliminate diagnostic
errors, but results are often indistinguishable from
benign and malignant lesions; GS appears on T2 as
hyperintense, heterogeneous, well-defined [4, 7]. The
diagnosis is confirmed only by core biopsy and
histological examination.
Lumpectomy combined with systemic chemotherapy
results in a good outcome.
Some studies had
demonstrated that the overall survival was longer in
patients treated by chemotherapy compared with those
who did not receive chemotherapy [5-7]. However,
because of the limited number of GS cases in the
literature, therapeutic approaches remain controversial.
The pillar of treatment is systemic chemotherapy
with regimens normally utilized for AML [1, 8]. Several
studies and reviews have featured the significance of
early systemic therapy in order to accomplish a long,
disease-free survival and to avoid AML development or
relapse [9–13].
There is an absence of clear indication for
combination chemotherapy with radiotherapy since
survival rates appear to be equal, despite the fact that it
may be a valuable device for symptomatic relief or in
refractory disease. In addition, several retrospective
112

studies have shown a high rate of AML development in
patients with isolated GS experiencing radiotherapy or
surgery alone. Our case was unique due to the unusual
treatment management; we performed lumpectomy and
radiotherapy without chemotherapy with good
outcomes.
There is no clear consensus whether or not bone
marrow transplantation has an effect even though recent
studies have shown a significant survival benefit [10, 11,
13]. Finally, promising targeted therapies currently in
trial for AML, such as FLT3 inhibitors, farnesyltransferase inhibitors and histone deacetylase inhibitors,
might be an effective option against GS [10].
Histopathology and the immunohistochemistry
confirm the diagnostic. Macroscopically the tumors had
a green color, due to the MPO present in the myeloid
cells [3, 14]. Histological examination usually shows the
presence of the myeloblasts, these cells appeared pale on
hematoxylin and eosin stain, the nucleus was irregular
with finely granular chromatin with scanty cytoplasm
[3].
Immunohistochemical
usually
confirms
the
diagnosis. There is a large array of cytogenetic tests and
flow cytometry to distinguish GS from lymphoma [6, 7].
The tumor is often positive for MPO, CD117, CD99,
CD68, lysozyme, and nucleophosmin. The most frequent
cytogenetic and biochemical abnormalities carry t(8;
21), inv [14], and cytoplasmic expression of NPM and
FLT3-ITD [10].
Prognosis depends on some factors such as
cytogenetic profiles and age of onset. Some studies have
shown that the prognosis in isolated disease is better
than GS without medullary involvement [1, 5].

Highlights
Extramedullary manifestation of acute myeloid
leukemia are various, the breast mass in this context is
very rare, the aim of this report to keep on mind the
diagnosis of granulocytic sarcoma even the patient was in
complete remission.

Conclusions
GS of the breast is a rare manifestation of MDS. The
diagnosis is thus difficult to establish. GS can mimic other
neoplasms like lymphoma and breast carcinoma, so it can
be easily misdiagnosed without the immunohistochemistry
which uses a vast panel of markers. The management of
this disease remains unclear; some studies have concluded
that lumpectomy combined with systemic chemotherapy
may give good results.
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